Biochip: microarray-based diagnoses of Acute Myeloid Leukaemia
Crosslinks is producing a robust diagnostic analysis platform to support Skyline Diagnostics in their efforts to deliver microarray-based diagnoses of Acute Myeloid Leukaemia (AML). These results will enable speedy and accurate identification of Leukaemia sub-types so that the most effective subtype-specific treatments can be employed as quickly as possible. The Biochip project is funded through the CTMM (Centre for Translational Molecular Medicine) initiative. Our platform is designed to be compliant with the stringent demands of the United States Federal Drug Agency (FDA) and it is envisaged that it will be available, either as software as a service (SAAS) or as an “in house” solution, for other biotech companies with similar microarray-based diagnostics efforts.